Epigallocatechin-3-gallate Attenuates Myocardial Reperfusion Injury in Rats Through Activation of PI3K/Akt Signaling Pathway

HU Jia, GU Jun, XU Fei. et al

Abstract

This study was designed to investigate whether epigallocatechin-3-gallate (EGCG) postconditioning protects the heart against ischemic-reperfusion injury (IRI), and to explore its potential mechanisms in a rat model. Methods Male Wistar rats were subjected to myocardial ischemia (30 min) and reperfusion (up to 2 h) and the rats were divided into sham group (SO) group, ischemia-reperfusion (I/R) model group and EGCG group. EGCG group were treated with EGCG (10 mg/kg) via intravenous infusion 5 min before reperfusion. Electrocardiogram were applied to record ventricular arrhythmia frequency. The severity of myocardial injury 〔serum level of lactate dehydrogenase (LDH) and creatine kinase (CK), hematoxylineosin (HE) staining〕 and ventricular arrhythmia, and the serum levels of inflammatory cytokines 〔tumor necrosis factor-α (TNF-α), interleukins-6 (IL-6) and IL-8〕 were assessed with ELISA, electrocardiogram and Western blot respectively. Results EGCG given before reperfusion could effectively reduce the serum level of LDH and CK and the incidence of ventricular arrhythmia (P<0.05, respectively), improved the pathological damage. Meanwhile, EGCG could down-regulate the expression levels of TNF-α, IL-6, IL-8 in the myocardial tissue after IRI (P<0.05,repectively). The expression levels of p-p85 and p-Akt in the EGCG group were significantly up-regulated compared to those in I/R group (P<0.05, repectively). Conclusion EGCG-related anti-inflammatory action could attenuate rat myocardial IRI and this cardioprotective effect might be activated through the PI3K/Akt pathway.

 

Keywords: Epigallocatechin Ischemia reperfusion injury, Myocardial infarction, PI3K/Akt Inflammation 

 

 

Full Text:

PDF


References


MINAMINO T. Cardioprotection from ischemia/reperfusion injury: basic and translational research. Circ J.2012.76(5): 1074-1082.

HAUSENLOY DJ. YELLON DM. Myocardial ischemia- reperfusion injury; a neglected therapeutic target. J Clin Invest<.2013-123(1):92-100.

KAKUTA Y, OKUMI M. ISAKA Y, et al. Epigallocatechin-3-gallate protects kidneys from ischemia reperfusion injury by HQ-1 upregulation and inhibition of macrophage infiltration. Transpl Int.2011,24(5):514-522.

ANEJA R, HAKE PW, BURROUGHS TJ, et al. Epigallocatechin, a green tea polyphenol. Attenuates myocardial ischemia reperfusion injury in rats. Mol Med. 2004.10(1/2/3/4/5/6):55-62.

GIAKOUSTIDIS DE. GIAKOUSTIDIS АЕ, ILIADIS S. et al. Attenuation of liver ischemia/reperfusion induced apoptosis by epigallocatechin-3-gallate via down-regulation of NF-kappaB and c-Jun expression. J Surg Res,2010,159(2): 720-728.

MILLER LE, HOSICK PA, WRIEDEN J, et al. Evaluation of arrhythmia scoring systems and exercise-induced cardioprotection. Med Sci Sports Exerc, 2012, 44 ( 3 ); 435- 441.

HU G, HUANG X, ZHANG K, et al. Anti-inflammatory effect of В-type natriuretic peptide postconditioning during myocardial ischemia-reperfusion: involvement of PI3K/Akt signaling pathway. Inflammation.2014 .37(5): 1669-1674.

WILLIAMS DL, OZMENT-SKELTON T, LI C. Modulation of the phosphoinositide 3-kinase signaling pathway alters host response to sepsis, inflammation, and ischemia/reperfusion injury. Shock,2006.25(5) ; 432-439.

KIM JA, FORMOSO G, LI Y, et al. Epigallocatechin gallate, a green tea polyphenol, mediates NO-dependent vasodilation using signaling pathways in vascular endothelium requiring reactive oxygen species and Fyn. J Biol Chem, 2007,282(18):13736-13745.

ELBLING L, WEISS RM, TEUFELHOFER O, et al. Green tea extract and ( — )-epigallocatechin-3-gallate, the major tea catechin. exert oxidant but lack antioxidant activities. FASEB J, 2005,19(7):807-809.

POTENZA MA, MARASCIULO FL, TARQUINIO M, et al. EGCG, a green tea polyphenol, improves endothelial function and insulin sensitivity, reduces blood pressure, and protects against myocardial I/R injury in SHR. Am J Physiol Endocrinol Metab.2007.292(5) :E1378- El387.

Al W. ZHANG Y. TANG QZ, et al. Silibinin attenuates cardiac hypertrophy and fibrosis through blocking EGFR- dependent signaling. J Cell Biochem, 2010, 110 ( 5) ; 1111- 1122.


Refbacks

  • There are currently no refbacks.